<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03500419</url>
  </required_header>
  <id_info>
    <org_study_id>18-001013</org_study_id>
    <nct_id>NCT03500419</nct_id>
  </id_info>
  <brief_title>Penile Length Maintenance Post-Prostatectomy</brief_title>
  <official_title>Penile Length Maintenance Post-Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the current study is to evaluate the efficacy of a novel, class I (ie.&#xD;
      lowest risk, clinical studies not required) medical penile traction device in preventing loss&#xD;
      of penile length in men undergoing robotic-assisted prostatectomy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The treatment of prostate cancer results in several known sexual dysfunctions, including&#xD;
      erectile dysfunction, orgasmic dysfunction, ejaculatory dysfunction, penile curvature&#xD;
      (Peyronie's disease), and reduced penile length. Among the dysfunctions, loss of penile&#xD;
      length is often one that results in significant distress and bother to patients. Beyond the&#xD;
      esthetic concerns, reduced penile length may lead to inability to participate in sexual&#xD;
      intercourse, difficulty with future interventions to restore erectile function, and lead to&#xD;
      worsened urinary hygiene.&#xD;
&#xD;
      Penile traction therapy (PTT) is currently the best available treatment to maintain or&#xD;
      restore lost penile length due to conditions that reduce length. To date, no studies have&#xD;
      evaluated the benefits of using PTT in this clinical setting. The objective of the current&#xD;
      study is to evaluate the efficacy of a novel penile traction device (RestoreX®), created and&#xD;
      funded through Mayo Ventures, in maintaining or restoring reduced penile length.&#xD;
&#xD;
      To accomplish the study, a population of men from Mayo Clinic who have undergone a&#xD;
      prostatectomy will be enrolled and randomized to utilize the device for varying amounts of&#xD;
      time. Outcomes will be assessed at 6 and 9 months post-prostatectomy and results are to be&#xD;
      used with the intent to publish in a scientific journal.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 23, 2018</start_date>
  <completion_date type="Actual">December 28, 2020</completion_date>
  <primary_completion_date type="Actual">December 28, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Penile Length</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Stretched penile length measured in centimeters from pubic symphysis to glanular corona</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Erectogenic Therapy Use</measure>
    <time_frame>6 months</time_frame>
    <description>The percentage of subjects to use a phosphodiesterase-5 inhibitor for erectogenic therapy use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracavernosal Injections</measure>
    <time_frame>6 months</time_frame>
    <description>The percentage of subjects to use intracavernosal injections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Erectile Function Domain of International Index of Erectile Function (IIEF)</measure>
    <time_frame>baseline, 6 months</time_frame>
    <description>Erectile function domain will be measured by using the International Index of Erectile Function (IIEF) questionnaire. IIEF is a validated, 15-item questionnaire that assesses 5 domains of sexual function: erectile function (range 1-30), orgasmic function (range 0-10), sexual desire (range 2-10), intercourse satisfaction (range 0-15), and overall sexual satisfaction (range 2-10). Each question was answered on a 6-point or 5-point scale from 0/1 to 5 (best) with a total possible score (sum of 5 domains) range of 5 to 75 with higher scores representing better function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Intercourse Satisfaction Domain of International Index of Erectile Function (IIEF)</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Intercourse satisfaction will be measured by using the International Index of Erectile Function (IIEF) questionnaire. IIEF is a validated, 15-item questionnaire that assesses 5 domains of sexual function: erectile function (range 1-30), orgasmic function (range 0-10), sexual desire (range 2-10), intercourse satisfaction (range 0-15), and overall sexual satisfaction (range 2-10). Each question was answered on a 6-point or 5-point scale from 0/1 to 5 (best) with a total possible score (sum of 5 domains) range of 5 to 75 with higher scores representing better function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Overall Satisfaction Domain of International Index of Erectile Function (IIEF)</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Overall satisfaction domain will be measured by using the International Index of Erectile Function (IIEF) questionnaire. IIEF is a validated, 15-item questionnaire that assesses 5 domains of sexual function: erectile function (range 1-30), orgasmic function (range 0-10), sexual desire (range 2-10), intercourse satisfaction (range 0-15), and overall sexual satisfaction (range 2-10). Each question was answered on a 6-point or 5-point scale from 0/1 to 5 (best) with a total possible score (sum of 5 domains) range of 5 to 75 with higher scores representing better function.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Penile Diseases</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>No treatment will be administered for the initial 6 months post-prostatectomy. This is necessary as a measure to review post-prostatectomy penile length changes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group AB - PTT 1-2x daily x 5-7 days/week x 5 months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Men will utilize penile traction therapy for 30 minutes 1-2 times daily, 5-7 times a week, beginning 4 weeks post-prostatectomy. Men will remain in this phase for a period of 5 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RestoreX</intervention_name>
    <description>PTT - Penile traction therapy in the straight position.</description>
    <arm_group_label>Group AB - PTT 1-2x daily x 5-7 days/week x 5 months</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No treatment</intervention_name>
    <description>Control group. No treatment will be given for the 6 months post-prostatectomy</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Undergoing robotic prostatectomy&#xD;
&#xD;
          -  Seen in the post-prostatectomy rehab clinic&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        • Urethral complications from prostatectomy at the time of baseline visit&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Ziegelmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 9, 2018</study_first_submitted>
  <study_first_submitted_qc>April 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2018</study_first_posted>
  <results_first_submitted>September 28, 2021</results_first_submitted>
  <results_first_submitted_qc>September 28, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 20, 2021</results_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Matthew (Matt) J. Ziegelmann</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Penile Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 3, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/19/NCT03500419/Prot_SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control</title>
          <description>No treatment was administered for the initial 6 months post-prostatectomy. This is necessary as a measure to review post-prostatectomy penile length changes.&#xD;
No treatment: Control group. No treatment was given for the 6 months post-prostatectomy</description>
        </group>
        <group group_id="P2">
          <title>PTT 1-2x Daily x 5-7 Days/Week x 5 Months</title>
          <description>Men utilized penile traction therapy for 30 minutes 1-2 times daily, 5-7 times a week, beginning 4 weeks post-prostatectomy for a period of 5 months.&#xD;
RestoreX: PTT - Penile traction therapy in the straight position.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control</title>
          <description>No treatment was administered for the initial 6 months post-prostatectomy. This is necessary as a measure to review post-prostatectomy penile length changes.&#xD;
No treatment: Control group. No treatment was given for the 6 months post-prostatectomy</description>
        </group>
        <group group_id="B2">
          <title>PTT 1-2x Daily x 5-7 Days/Week x 5 Months</title>
          <description>Men utilized penile traction therapy for 30 minutes 1-2 times daily, 5-7 times a week, beginning 4 weeks post-prostatectomy for a period of 5 months.&#xD;
RestoreX: PTT - Penile traction therapy in the straight position.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="55"/>
            <count group_id="B3" value="82"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.2" spread="4.5"/>
                    <measurement group_id="B2" value="58.7" spread="6.8"/>
                    <measurement group_id="B3" value="58.6" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Penile Length</title>
        <description>Stretched penile length measured in centimeters from pubic symphysis to glanular corona</description>
        <time_frame>Baseline, 6 months</time_frame>
        <population>6 months data was not collected nor analyzed for 2 subjects in control arm and 25 subjects in PTT arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>No treatment was administered for the initial 6 months post-prostatectomy. This is necessary as a measure to review post-prostatectomy penile length changes.&#xD;
No treatment: Control group. No treatment was given for the 6 months post-prostatectomy</description>
          </group>
          <group group_id="O2">
            <title>PTT 1-2x Daily x 5-7 Days/Week x 5 Months</title>
            <description>Men utilized penile traction therapy for 30 minutes 1-2 times daily, 5-7 times a week, beginning 4 weeks post-prostatectomy for a period of 5 months.&#xD;
RestoreX: PTT - Penile traction therapy in the straight position.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Penile Length</title>
          <description>Stretched penile length measured in centimeters from pubic symphysis to glanular corona</description>
          <population>6 months data was not collected nor analyzed for 2 subjects in control arm and 25 subjects in PTT arm.</population>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="1.5"/>
                    <measurement group_id="O2" value="1.6" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Erectogenic Therapy Use</title>
        <description>The percentage of subjects to use a phosphodiesterase-5 inhibitor for erectogenic therapy use</description>
        <time_frame>6 months</time_frame>
        <population>6 months data was not collected nor analyzed for 2 subjects in control arm and 25 subjects in PTT arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>No treatment was administered for the initial 6 months post-prostatectomy. This is necessary as a measure to review post-prostatectomy penile length changes.&#xD;
No treatment: Control group. No treatment was given for the 6 months post-prostatectomy</description>
          </group>
          <group group_id="O2">
            <title>PTT 1-2x Daily x 5-7 Days/Week x 5 Months</title>
            <description>Men utilized penile traction therapy for 30 minutes 1-2 times daily, 5-7 times a week, beginning 4 weeks post-prostatectomy for a period of 5 months.&#xD;
RestoreX: PTT - Penile traction therapy in the straight position.</description>
          </group>
        </group_list>
        <measure>
          <title>Erectogenic Therapy Use</title>
          <description>The percentage of subjects to use a phosphodiesterase-5 inhibitor for erectogenic therapy use</description>
          <population>6 months data was not collected nor analyzed for 2 subjects in control arm and 25 subjects in PTT arm.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intracavernosal Injections</title>
        <description>The percentage of subjects to use intracavernosal injections</description>
        <time_frame>6 months</time_frame>
        <population>6 months data was not collected nor analyzed for 2 subjects in control arm and 25 subjects in PTT arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>No treatment was administered for the initial 6 months post-prostatectomy. This is necessary as a measure to review post-prostatectomy penile length changes.&#xD;
No treatment: Control group. No treatment was given for the 6 months post-prostatectomy</description>
          </group>
          <group group_id="O2">
            <title>PTT 1-2x Daily x 5-7 Days/Week x 5 Months</title>
            <description>Men utilized penile traction therapy for 30 minutes 1-2 times daily, 5-7 times a week, beginning 4 weeks post-prostatectomy for a period of 5 months.&#xD;
RestoreX: PTT - Penile traction therapy in the straight position.</description>
          </group>
        </group_list>
        <measure>
          <title>Intracavernosal Injections</title>
          <description>The percentage of subjects to use intracavernosal injections</description>
          <population>6 months data was not collected nor analyzed for 2 subjects in control arm and 25 subjects in PTT arm.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Erectile Function Domain of International Index of Erectile Function (IIEF)</title>
        <description>Erectile function domain will be measured by using the International Index of Erectile Function (IIEF) questionnaire. IIEF is a validated, 15-item questionnaire that assesses 5 domains of sexual function: erectile function (range 1-30), orgasmic function (range 0-10), sexual desire (range 2-10), intercourse satisfaction (range 0-15), and overall sexual satisfaction (range 2-10). Each question was answered on a 6-point or 5-point scale from 0/1 to 5 (best) with a total possible score (sum of 5 domains) range of 5 to 75 with higher scores representing better function.</description>
        <time_frame>baseline, 6 months</time_frame>
        <population>6 months data was not collected nor analyzed for 2 subjects in control arm and 25 subjects in PTT arm. Negative denotes loss of function.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>No treatment was administered for the initial 6 months post-prostatectomy. This is necessary as a measure to review post-prostatectomy penile length changes.&#xD;
No treatment: Control group. No treatment was given for the 6 months post-prostatectomy</description>
          </group>
          <group group_id="O2">
            <title>PTT 1-2x Daily x 5-7 Days/Week x 5 Months</title>
            <description>Men utilized penile traction therapy for 30 minutes 1-2 times daily, 5-7 times a week, beginning 4 weeks post-prostatectomy for a period of 5 months.&#xD;
RestoreX: PTT - Penile traction therapy in the straight position.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Erectile Function Domain of International Index of Erectile Function (IIEF)</title>
          <description>Erectile function domain will be measured by using the International Index of Erectile Function (IIEF) questionnaire. IIEF is a validated, 15-item questionnaire that assesses 5 domains of sexual function: erectile function (range 1-30), orgasmic function (range 0-10), sexual desire (range 2-10), intercourse satisfaction (range 0-15), and overall sexual satisfaction (range 2-10). Each question was answered on a 6-point or 5-point scale from 0/1 to 5 (best) with a total possible score (sum of 5 domains) range of 5 to 75 with higher scores representing better function.</description>
          <population>6 months data was not collected nor analyzed for 2 subjects in control arm and 25 subjects in PTT arm. Negative denotes loss of function.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.5" lower_limit="-21.5" upper_limit="-2"/>
                    <measurement group_id="O2" value="0" lower_limit="-7.5" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Intercourse Satisfaction Domain of International Index of Erectile Function (IIEF)</title>
        <description>Intercourse satisfaction will be measured by using the International Index of Erectile Function (IIEF) questionnaire. IIEF is a validated, 15-item questionnaire that assesses 5 domains of sexual function: erectile function (range 1-30), orgasmic function (range 0-10), sexual desire (range 2-10), intercourse satisfaction (range 0-15), and overall sexual satisfaction (range 2-10). Each question was answered on a 6-point or 5-point scale from 0/1 to 5 (best) with a total possible score (sum of 5 domains) range of 5 to 75 with higher scores representing better function.</description>
        <time_frame>Baseline, 6 months</time_frame>
        <population>6 months data was not collected nor analyzed for 2 subjects in control arm and 25 subjects in PTT arm. Negative denotes loss of function.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>No treatment was administered for the initial 6 months post-prostatectomy. This is necessary as a measure to review post-prostatectomy penile length changes.&#xD;
No treatment: Control group. No treatment was given for the 6 months post-prostatectomy</description>
          </group>
          <group group_id="O2">
            <title>PTT 1-2x Daily x 5-7 Days/Week x 5 Months</title>
            <description>Men utilized penile traction therapy for 30 minutes 1-2 times daily, 5-7 times a week, beginning 4 weeks post-prostatectomy for a period of 5 months.&#xD;
RestoreX: PTT - Penile traction therapy in the straight position.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Intercourse Satisfaction Domain of International Index of Erectile Function (IIEF)</title>
          <description>Intercourse satisfaction will be measured by using the International Index of Erectile Function (IIEF) questionnaire. IIEF is a validated, 15-item questionnaire that assesses 5 domains of sexual function: erectile function (range 1-30), orgasmic function (range 0-10), sexual desire (range 2-10), intercourse satisfaction (range 0-15), and overall sexual satisfaction (range 2-10). Each question was answered on a 6-point or 5-point scale from 0/1 to 5 (best) with a total possible score (sum of 5 domains) range of 5 to 75 with higher scores representing better function.</description>
          <population>6 months data was not collected nor analyzed for 2 subjects in control arm and 25 subjects in PTT arm. Negative denotes loss of function.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" lower_limit="-7.0" upper_limit="0"/>
                    <measurement group_id="O2" value="1" lower_limit="-2" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Overall Satisfaction Domain of International Index of Erectile Function (IIEF)</title>
        <description>Overall satisfaction domain will be measured by using the International Index of Erectile Function (IIEF) questionnaire. IIEF is a validated, 15-item questionnaire that assesses 5 domains of sexual function: erectile function (range 1-30), orgasmic function (range 0-10), sexual desire (range 2-10), intercourse satisfaction (range 0-15), and overall sexual satisfaction (range 2-10). Each question was answered on a 6-point or 5-point scale from 0/1 to 5 (best) with a total possible score (sum of 5 domains) range of 5 to 75 with higher scores representing better function.</description>
        <time_frame>Baseline, 6 months</time_frame>
        <population>6 months data was not collected nor analyzed for 2 subjects in control arm and 25 subjects in PTT arm. Negative denotes loss of function.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>No treatment was administered for the initial 6 months post-prostatectomy. This is necessary as a measure to review post-prostatectomy penile length changes.&#xD;
No treatment: Control group. No treatment was given for the 6 months post-prostatectomy</description>
          </group>
          <group group_id="O2">
            <title>PTT 1-2x Daily x 5-7 Days/Week x 5 Months</title>
            <description>Men utilized penile traction therapy for 30 minutes 1-2 times daily, 5-7 times a week, beginning 4 weeks post-prostatectomy for a period of 5 months.&#xD;
RestoreX: PTT - Penile traction therapy in the straight position.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Overall Satisfaction Domain of International Index of Erectile Function (IIEF)</title>
          <description>Overall satisfaction domain will be measured by using the International Index of Erectile Function (IIEF) questionnaire. IIEF is a validated, 15-item questionnaire that assesses 5 domains of sexual function: erectile function (range 1-30), orgasmic function (range 0-10), sexual desire (range 2-10), intercourse satisfaction (range 0-15), and overall sexual satisfaction (range 2-10). Each question was answered on a 6-point or 5-point scale from 0/1 to 5 (best) with a total possible score (sum of 5 domains) range of 5 to 75 with higher scores representing better function.</description>
          <population>6 months data was not collected nor analyzed for 2 subjects in control arm and 25 subjects in PTT arm. Negative denotes loss of function.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3" lower_limit="-6" upper_limit="-1"/>
                    <measurement group_id="O2" value="0" lower_limit="-2.8" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from baseline until end of intervention, approximately 6 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Control</title>
          <description>No treatment was administered for the initial 6 months post-prostatectomy. This is necessary as a measure to review post-prostatectomy penile length changes.&#xD;
No treatment: Control group. No treatment was given for the 6 months post-prostatectomy</description>
        </group>
        <group group_id="E2">
          <title>PTT 1-2x Daily x 5-7 Days/Week x 5 Months</title>
          <description>Men utilized penile traction therapy for 30 minutes 1-2 times daily, 5-7 times a week, beginning 4 weeks post-prostatectomy for a period of 5 months.&#xD;
RestoreX: PTT - Penile traction therapy in the straight position.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Temporary mile penile discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Temporary penile erythema or discoloration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Matthew (Matt) J. Ziegelmann, M.D.</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-266-3982</phone>
      <email>Ziegelmann.Matthew@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

